In July, NPM Capital has obtained an interest of nearly 25% in Hendrix Genetics, one of the main suppliers of animals and eggs for breeding purposes in the world. In doing so, the Brabant enterprise is ready for a new growth phase and further professionalization. The family business has grown from 50 to 2500 employees the past decade, partly due to a substantial number of takeovers. However, it is expected that the highly competitive international market will make new investments, particularly in R&D, essential. The participation of NPM Capital makes an accelerated execution of this strategy possible.
Hendrix is a global player in the field of genetic enrichment of animals and eggs for breeding purposes. In addition to animals and eggs, the company is also active in software development for breeding programs. The company is highly innovative and invests a lot in research.
The DNA of the family business (a majority of shares is owned by the Hendrix family) perfectly matches that of NPM Capital. The company’s activities have a typical long-term character: it generally takes five to ten years before breeding companies can reap the rewards from their research efforts. This matches the ‘open horizon’ investment philosophy of NPM Capital to which a contribution to long-term value creation of its participations is paramount.
Ambitious
According to Johan Terpstra, Investment Director of NPM Capital, Hendrix Genetics is “an ambitious enterprise with involved shareholders, capable management, and an excellent buy & build track record. Their mission – to make the production of animal proteins more efficient, sustainable, and affordable and, by doing so, being better able to fulfil the food demand of the world – seamlessly matches our participation objectives.”
Antoon van den Berg, CEO, fellow shareholder and co-founder of Hendrix Genetics, is pleased that Hendrix’s ambitions can be better realized with NPM: “Additionally, the fact that we run the company as a family guarantees passion and fast decision making, which is crucial for the future of the company.”
Hendrix Genetics will continue to run the company according to the same strategy and in the same structure under the current management and existing management team. Furthermore, the existing corporate governance structure of Hendrix will also be maintained.
